C-PJFVNeuroNascent Inc (NNI)
oral small molecules, neurogenesis, neuron regeneration
replacementreplacingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-PJFV
C-PJFVC-PJFVoral small molecules, neurogenesis, neuron regeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
NeuroNascent Inc (NNI) oral small molecules, neurogenesis, neuron regeneration
NeuroNascent is a privately held biopharmaceutical company developing orally available, small-molecule therapies intended to halt or reverse central nervous system diseases. Its lead candidate, NNI-362, is described as a neuron regenerative therapy for Alzheimer's disease, Parkinson's disease and age-related disorders, with Phase 1a human safety testing completed. The company also lists NNI-351 for Fragile X syndrome and Down syndrome, NNI-370 for Parkinson's disease, and Cajuvenate as the veterinary-use name for NNI-362 in Canine Cognitive Dysfunction.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
NeuroNascent Inc (NNI) — Translational · Lower middle. Derived deterministically from 4 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic